ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AMGN Amgen Inc

99.323
0.012 (0.01%)
20 Dec 2024 - Closed
Realtime Data
Name Symbol Market Type
Amgen Inc TG:AMGN Tradegate Bond
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.012 0.01% 99.323 99.096 99.55 0 22:50:20

Amgen to Present at Lazard Capital Healthcare Conference

16/11/2009 11:06pm

PR Newswire (US)


Amgen (TG:AMGN)
Historical Stock Chart


From Dec 2019 to Dec 2024

Click Here for more Amgen Charts.
THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, http://www.amgen.com/, under Investors. Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar. About Amgen Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com/. CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 or 805-490-0661 (media) Justin Claeys, 805-447-1060 (investors) (Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO) http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO http://photoarchive.ap.org/ DATASOURCE: Amgen CONTACT: media, David Polk, +1-805-447-4613, +1-805-490-0661, investors, Justin Claeys, +1-805-447-1060, both of Amgen, Thousand Oaks Web Site: http://www.amgen.com/

Copyright

1 Year Amgen Chart

1 Year Amgen Chart

1 Month Amgen Chart

1 Month Amgen Chart